Szikszai, K.; Krejcik, Z.; Klema, J.; Loudova, N.; Hrustincova, A.; Belickova, M.; Hruba, M.; Vesela, J.; Stranecky, V.; Kundrat, D.; Pecherkova, P.; Cermak, J.; Jonasova, A.; Dostalova Merkerova, M.

LncRNA profiling reveals that the deregulation of H19, WT1-AS, TCL6, and LEF1-AS1 is associated with higher-risk myelodysplastic syndrome

[rok vydání 2020, impact factor 6.639 ]

Koralkova, P.; Belickova, M.; Kundrat, D.; Dostalova Merkerova, M.; Krejcik, Z.; Szikszai, K.; Kaisrlikova, M.; Vesela, J.; Vyhlidalova, P.; Stetka, J.; Hlavackova, A.; Suttnar, J.; Flodr, P.; Stritesky, J.; Jonasova, A.; Cermak, J.; Divoky, V.

Low plasma citrate levels and specific transcriptional signatures associated with quiescence of CD34+ progenitors predict Azacitidine therapy failure in MDS/AML patients

[rok vydání 2021, impact factor 6.639 ]

Hrustincova, A.; Krejcik, Z.; Kundrat, D.; Szikszai, K.; Belickova, M.; Pecherkova, P.; Klema, J.; Vesela, J.; Hruba, M.; Cermak, J.; Hrdinova, T.; Krijt, M.; Valka, J.; Jonasova, A.; Merkerova, M.D.

Circulating small noncoding RNAs have specific expression patterns in plasma and extracellular vesicles in myelodysplastic syndromes and are predictive of patient outcome

[rok vydání 2020, impact factor 6.600 ]

Belickova, M.; Vesela, J.; Jonasova, A.; Pejsova, B.; Votavova, H.; Dostalova Merkerova, M.; Zemanova, Z.; Brezinova, J.; Mikulenkova, D.; Lauermannova, M.; Valka, J.; Michalova, K.; Neuwirtova, R.; Cermak, J.

TP53 mutation variant allele frequency is a potential predictor for clinical outcome of patients with lower-risk myelodysplastic syndromes

[rok vydání 2016, impact factor 5.168 ]

Svobodova, K.; Lhotska, H.; Hodanova, L.; Pavlistova, L.; Vesela, D.; Belickova, M.; Vesela, J.; Brezinova, J.; Sarova, I.; Izakova, S.; Lizcova, L.; Siskova, M.; Jonasova, A.; Cermak, J.; Michalova, K.; Zemanova, Z.

Cryptic aberrations may allow more accurate prognostic classification of patients with myelodysplastic syndromes and clonal evolution

[rok vydání 2020, impact factor 5.006 ]

Belickova, M.; Merkerova, M.D.; Stara, E.; Vesela, J.; Sponerova, D.; Mikulenkova, D.; Brdicka, R.; Neuwirtova, R.; Jonasova, A.; Cermak, J.

DNA repair gene variants are associated with an increased risk of myelodysplastic syndromes in a Czech population

[rok vydání 2013, impact factor 4.933 ]

Valka, J.; Vesela, J.; Votavova, H.; Dostalova-Merkerova, M.; Horakova, Z.; Campr, V.; Brezinova, J.; Zemanova, Z.; Jonasova, A.; Cermak, J.; Belickova, M.

Differential expression of homologous recombination DNA repair genes in the early and advanced stages of myelodysplastic syndrome

[rok vydání 2017, impact factor 2.595 ]

Valka, J.; Vesela, J.; Votavova, H.; Dostalova-Merkerova, M.; Urbanova, Z.; Jonasova, A.; Cermak, J.; Belickova, M.

Genetic variant screening of DNA repair genes in myelodysplastic syndrome identifies a novel mutation in the XRCC2 gene

[rok vydání 2019, impact factor 1.967 ]

Belickova, M.; Cermak, J.; Dostalova Merkerova, M.; Vesela, J.; Krejcik, Z.; Cechova, E.; Zemanova, Z.; Michalova, K.; Votavova, H.; Caniga, M.; Neuwirtova, R.; Jonasova, A.

Changes associated with lenalidomide treatment in the gene expression profiles of patients with del(5q)

[rok vydání 2012, impact factor 1.667 ]

Belickova, M.; Dostalova Merkerova, M.; Votavova, H.; Valka, J.; Vesela, J.; Pejsova, B.; Hajkova, H.; Klema, J.; Cermak, J.; Jonasova, A.

Up-regulation of ribosomal genes is associated with a poor response to azacitidine in myelodysplasia and related neoplasms

[rok vydání 2016, impact factor 1.610 ]

Kaisrlikova, M.; Vesela, J.; Kundrat, D.; Votavova, H.; Dostalova Merkerova, M.; Krejcik, Z.; Divoky, V.; Jedlicka, M.; Fric, J.; Klema, J.; Mikulenkova, D.; Stastna Markova, M.; Lauermannova, M.; Mertova, J.; Soukupova Maaloufova, J.; Jonasova, A.; Cermak, J.; Belickova, M.

RUNX1 mutations contribute to the progression of MDS due to disruption of antitumor cellular defense: a study on patients with lower-risk MDS

[rok vydání 2022 ]